Can Immunotherapy Specifically Target Acute Myeloid Leukemic Stem Cells?

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2013 Mar 26

PMID 23526057

Citations 9

Authors

Sylvia Snauwaert

Bart Vandekerckhove

Tessa Kerre

Affiliations

Soon will be listed here.

Abstract

Accumulating evidence supports the role of leukemic stem cells (LSCs) in the high relapse rate of acute myeloid leukemia (AML) patients. The clinical relevance of LSCs, which were originally characterized in xenograft models, has recently been confirmed by the finding that stem cell-like gene expression signatures can predict the clinical outcome of AML patients. The targeted elimination of LSCs might hence constitute an efficient therapeutic approach to AML. Here, we review immunotherapeutic strategies that target LSC-associated antigens, including T cell-mediated and monoclonal antibody-based regimens. Attention is given to the issue of antigen specificity because this is relevant to the therapeutic window and determines the superiority of LSC-targeting immunotherapy.

Citing Articles

Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.

Greiner J, Gotz M, Hofmann S, Schrezenmeier H, Wiesneth M, Bullinger L Cancer Immunol Immunother. 2020; 69(4):629-640.

PMID: 32020256 PMC: 11027801. DOI: 10.1007/s00262-020-02490-2.

Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.

Narayan R, Olsson N, Wagar L, Medeiros B, Meyer E, Czerwinski D PLoS One. 2019; 14(7):e0219547.

PMID: 31291378 PMC: 6619824. DOI: 10.1371/journal.pone.0219547.

Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia.

Van Acker H, Versteven M, Lichtenegger F, Roex G, Campillo-Davo D, Lion E J Clin Med. 2019; 8(5).

PMID: 31035598 PMC: 6572115. DOI: 10.3390/jcm8050579.

A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia.

Oda S, Daman A, Garcia N, Wagener F, Schmitt T, Tan X Blood. 2017; 130(22):2410-2419.

PMID: 29042364 PMC: 5709784. DOI: 10.1182/blood-2017-04-777052.

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.

Ye B, Stary C, Gao Q, Wang Q, Zeng Z, Jian Z J Immunol Res. 2017; 2017:5210459.

PMID: 28116322 PMC: 5237740. DOI: 10.1155/2017/5210459.

References

Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T . Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood. 2008; 113(1):66-74. DOI: 10.1182/blood-2008-06-164889. View

Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A . Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003; 9(9):1158-65. DOI: 10.1038/nm909. View

Kaname T, Yanagi K, Chinen Y, Makita Y, Okamoto N, Maehara H . Mutations in CD96, a member of the immunoglobulin superfamily, cause a form of the C (Opitz trigonocephaly) syndrome. Am J Hum Genet. 2007; 81(4):835-41. PMC: 2227933. DOI: 10.1086/522014. View

van Rhenen A, Feller N, Kelder A, Westra A, Rombouts E, Zweegman S . High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005; 11(18):6520-7. DOI: 10.1158/1078-0432.CCR-05-0468. View

Fatrai S, Schepers H, Tadema H, Vellenga E, Daenen S, Schuringa J . Mucin1 expression is enriched in the human stem cell fraction of cord blood and is upregulated in majority of the AML cases. Exp Hematol. 2008; 36(10):1254-65. DOI: 10.1016/j.exphem.2008.04.015. View

Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T . Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood. 1996; 87(11):4789-96. View

Jordan C, Upchurch D, Szilvassy S, Guzman M, Howard D, PETTIGREW A . The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14(10):1777-84. DOI: 10.1038/sj.leu.2401903. View

Gentles A, Plevritis S, Majeti R, Alizadeh A . Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA. 2010; 304(24):2706-15. PMC: 4089862. DOI: 10.1001/jama.2010.1862. View

Anguille S, Van Tendeloo V, Berneman Z . Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia. 2012; 26(10):2186-96. DOI: 10.1038/leu.2012.145. View

10.

Kapp M, Stevanovic S, Fick K, Tan S, Loeffler J, Opitz A . CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplant. 2009; 43(5):399-410. DOI: 10.1038/bmt.2008.426. View

11.

van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint A, Zweegman S . Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 2007; 21(8):1700-7. DOI: 10.1038/sj.leu.2404754. View

12.

Taussig D, Miraki-Moud F, Anjos-Afonso F, Pearce D, Allen K, Ridler C . Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 2008; 112(3):568-75. DOI: 10.1182/blood-2007-10-118331. View

13.

Amadori S, Suciu S, Selleslag D, Stasi R, Alimena G, Baila L . Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA.... Br J Haematol. 2010; 149(3):376-82. PMC: 2864316. DOI: 10.1111/j.1365-2141.2010.08095.x. View

14.

Gao L, Bellantuono I, Elsasser A, Marley S, Gordon M, Goldman J . Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000; 95(7):2198-203. View

15.

Jin L, Hope K, Zhai Q, Smadja-Joffe F, Dick J . Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006; 12(10):1167-74. DOI: 10.1038/nm1483. View

16.

Vincenti F, Kirkman R, LIGHT S, Bumgardner G, Pescovitz M, Halloran P . Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998; 338(3):161-5. DOI: 10.1056/NEJM199801153380304. View

17.

van Rhenen A, van Dongen G, Kelder A, Rombouts E, Feller N, Moshaver B . The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007; 110(7):2659-66. DOI: 10.1182/blood-2007-03-083048. View

18.

Keilholz U, Letsch A, Busse A, Asemissen A, Bauer S, Blau I . A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009; 113(26):6541-8. DOI: 10.1182/blood-2009-02-202598. View

19.

Lowenberg B, Beck J, Graux C, van Putten W, Schouten H, Verdonck L . Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood. 2010; 115(13):2586-91. DOI: 10.1182/blood-2009-10-246470. View

20.

Kloosterboer F, van Luxemburg-Heijs S, van Soest R, Barbui A, van Egmond H, Strijbosch M . Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia. 2004; 18(4):798-808. DOI: 10.1038/sj.leu.2403297. View